The Avoca Quality Consortium announced its key initiatives for 2014.
The Avoca Quality Consortium announced its key initiatives for 2014, with a significant move to a change in its membership. That is it will offer Associate Consortium
Membership to companies that provide products and services in support of clinical development. This addresses what the Consortium believes will foster increased industry collaboration.
Other initiatives include:
The Consoritum was founded in 2012 as an opportunity to bring sponsors and CROs together to accelerate the development of best practices and industry standards for proactive quality management. The Avoca Quality Consortium is led by The Avoca Group, Inc., a Princeton-based consulting firm.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.